Cargando…
Opportunities and challenges in psychopharmacology
This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787536/ https://www.ncbi.nlm.nih.gov/pubmed/31636486 http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz |
_version_ | 1783458285958987776 |
---|---|
author | Schulz, Pierre |
author_facet | Schulz, Pierre |
author_sort | Schulz, Pierre |
collection | PubMed |
description | This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be individually adapted to provide more efficacy and less toxicity. The series of advances described here show that these once utopian goals for psychiatric treatment are now real themes of research, indicating that the future path for psychopharmacology might not be as narrow and grim as considered during the last few decades.
|
format | Online Article Text |
id | pubmed-6787536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-67875362019-10-21 Opportunities and challenges in psychopharmacology
Schulz, Pierre Dialogues Clin Neurosci State of the Art This review addresses novel approaches for influencing the transcriptome, the epigenome, the microbiome, the proteome, and the energy metabolome. These innovations help develop psychotropic medications which will directly reach the molecular targets, leading to beneficial effects, and which will be individually adapted to provide more efficacy and less toxicity. The series of advances described here show that these once utopian goals for psychiatric treatment are now real themes of research, indicating that the future path for psychopharmacology might not be as narrow and grim as considered during the last few decades.
Les Laboratoires Servier 2019-06 /pmc/articles/PMC6787536/ /pubmed/31636486 http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz Text en © 2019, AICH – Servier GroupCopyright © 2019 AICH – Servier Group. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | State of the Art Schulz, Pierre Opportunities and challenges in psychopharmacology |
title | Opportunities and challenges in
psychopharmacology
|
title_full | Opportunities and challenges in
psychopharmacology
|
title_fullStr | Opportunities and challenges in
psychopharmacology
|
title_full_unstemmed | Opportunities and challenges in
psychopharmacology
|
title_short | Opportunities and challenges in
psychopharmacology
|
title_sort | opportunities and challenges in
psychopharmacology
|
topic | State of the Art |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787536/ https://www.ncbi.nlm.nih.gov/pubmed/31636486 http://dx.doi.org/10.31887/DCNS.2019.21.2/pschulz |
work_keys_str_mv | AT schulzpierre opportunitiesandchallengesinpsychopharmacology |